Peptide self-selection on TikTok: what the science actually supports

What did @xxsjnichols actually say?

The creator laid out her current peptide stack after a post-surgery break, naming CJC, MOTC (likely MOTS-c), NAD, and something she calls "glow" and "epimoralin" (almost certainly ipamorelin). She said she waited to restart because her peptides "are supporting muscle growth," energy, metabolism, and mitochondrial health. She also said the glow compound is "great for repairing tissue" and "awesome for post-surgery," and that ipamorelin helps with sleep and muscle repair. She avoided showing the products on camera to dodge platform flags, while insisting everything is "totally legal" and available at med spas or weight loss clinics.

To be fair to her: she's not claiming cures. She's framing this as personal optimization, not medical treatment. That matters when you're reading the science below.

Does the science back this up?

Some of it, partially. The peptides she's describing have legitimate research behind them, but almost none of that research is in healthy humans doing gym recovery. Most of it is rodent studies, in vitro work, or small clinical trials in people with metabolic disease. That gap between the lab and your post-surgery recovery plan is enormous.

CJC-1295 is a growth hormone-releasing hormone analogue. It does raise GH and IGF-1 levels in human trials. Teichman et al. (2006, Journal of Clinical Endocrinology and Metabolism) found sustained GH elevation with CJC-1295 in healthy adults, but that study used pharmaceutical-grade product, not compounded versions from a med spa. MOTS-c is genuinely interesting, a mitochondrial-derived peptide shown to improve insulin sensitivity in mice (Lee et al., 2015, Cell Metabolism), but human data is almost nonexistent. NAD precursor therapy has stronger human evidence for energy metabolism, though most trials use NMN or NR orally, not injectable NAD. Ipamorelin does stimulate GH release with a cleaner side-effect profile than older secretagogues, per Walker (2006, Growth Hormone and IGF Research).

What did they get wrong (or right)?

The creator got the general mechanism descriptions mostly right, but several claims are sloppy enough to be misleading in practice.

• "Epimoralin" for sleep: She almost certainly means ipamorelin. Ipamorelin does influence GH pulsatility, which correlates with sleep quality, but calling it a sleep aid is a stretch. There's no robust clinical trial showing it improves sleep in healthy adults.
• MOTS-c for metabolism: Plausible based on rodent data, but presenting it as a reliable metabolic tool for gym-goers is getting well ahead of the evidence. Lee et al. (2015) is compelling, but mice are not people.
• "Great for repairing tissue" post-surgery: This is the claim that needs the most scrutiny. If she's referring to GHK-Cu or a similar peptide in her "glow" compound, there is some evidence for wound healing (Pickart and Margolina, 2018, Symmetry), but using this framing right after surgery without physician clearance is risky advice to broadcast to 10,000 viewers.
• "Totally legal": Technically true in most U.S. states when obtained via a licensed prescriber. But many of these peptides are not FDA-approved drugs. They exist in a regulatory gray zone as compounded preparations. The legality is real, the safety oversight is limited.

Credit where it's due: she did say these support her goals specifically and didn't tell viewers to copy her stack. That's a meaningful disclaimer that a lot of peptide content skips entirely.

What should you actually know?

The peptides she's discussing are not snake oil, but they're also not the established clinical tools she implies. The evidence ladder looks like this: rodent studies, then small human trials in diseased populations, then healthy-adult data, then gym-recovery-specific data. Most of these peptides are on the second rung at best.

Getting peptides from a med spa or esthetician, as she suggests, also sidesteps something important: compounded peptides are not FDA-approved, purity and dosing accuracy vary by compounding pharmacy, and there is no standardized clinical protocol for most of these compounds in healthy people. A 2023 FDA statement flagged several peptides, including BPC-157 and TB-500, as not meeting the criteria for legal compounding under the FD&C Act. The regulatory picture is shifting fast.

Post-surgical use in particular warrants physician oversight, not TikTok stacks. Hormonal and growth-factor pathways interact with healing in complex ways that are genuinely not well understood at the population level. If you're recovering from surgery, this is a conversation for your surgeon, not a peptide influencer.